Lung cancer patients who have acquired gene mutations associated with resistance to tyrosine kinase inhibitors such as Iressa or Tarceva (1) can be identified far more accurately using a new mutation test kit from DxS.
Lung cancer patients who have acquired gene mutations associated with resistance to tyrosine kinase inhibitors such as Iressa or Tarceva (1) can be identified far more accurately using a new mutation test kit from DxS.
